ERBB2 and breast adenocarcinoma: The benzimidazole tubulin/microtubule inhibitor, mebendazole in combination with gemcitabine-(C4-amide)-[anti-EG-FR] and epirubicin-(C3-amide)-[anti-HER2/neu] produced higher levels of anti-neoplastic cytotoxicity against chemotherapeutic-resistant mammary adenocarcinoma than did the dual covalent immunochemotherapeutic combination alone (Figure.